Newsletters and Deep Dive digital magazine
In another example of the pharma industry embracing generative artificial intelligence (genAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibod
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio
Patient centricity has been a key focus for pharma in 2023. However, extending beyond the merely discursive topic into sustained and tangible action at scale has been somewhat limited.
We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.
It’s about that time of year when many global teams turn their attention towards annual strategic planning.
180+ Technical mRNA Specialists | 35+ Expert Speakers | 2 Content Streams
The surge of clinical breakthroughs in SGLT2s, GLP-1s and ERAs for CKD, significant advancements to strengthen proteinuria and GFR slope as surrogates for long-term outcomes, and a wave of
Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox